Neoadjuvant chemotherapy for early breast cancer

Bibliography

• Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Cancer 2004;100:2512-32
   PubMed Web of Science ®Google Scholar
• Boughey JC, Peintinger F, Meric-Bernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 2006;244:464-70
   PubMed Web of Science ®Google Scholar
• Kaufmann M, von MG, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18:1927-34
   PubMed Web of Science ®Google Scholar
• Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 2006;56:37-47
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Blumenschein GR, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983;51:763-8
   PubMed Web of Science ®Google Scholar
• Deo SV, Bhutani M, Shukla NK, et al. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0). J Surg Oncol 2003;84:192-7
   PubMed Web of Science ®Google Scholar
• Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907;46:1-9
   PubMedGoogle Scholar
• Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979;39:3861-5
   PubMed Web of Science ®Google Scholar
• Van Dierendonck JH, Keijzer R, Cornelisse CJ, et al. Surgically induced cytokinetic responses in experimental rat mammary tumor models. Cancer 1991;68:759-67
   PubMed Web of Science ®Google Scholar
• Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983;43:1488-92
   PubMed Web of Science ®Google Scholar
• Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33
   PubMedGoogle Scholar
• Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer.Cochrane Database Syst Rev 2007;2:CD005002
   PubMed Web of Science ®Google Scholar
• Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007;94:1189-200
   PubMed Web of Science ®Google Scholar
• Scholl SM, Asselain B, Palangie T, et al. Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 1991;27:1668-71
   PubMed Web of Science ®Google Scholar
• Broet P, Scholl SM, de la Rochefordiere A, et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 1999;58:151-6
   PubMed Web of Science ®Google Scholar
• Mauriac L, Macgrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Ann Oncol 1999;10:47-52
   PubMed Web of Science ®Google Scholar
• Bria E, Giannarelli D, Felici A, et al. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer 2005;103:672-9
   PubMed Web of Science ®Google Scholar
• Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006;106:2337-44
   PubMed Web of Science ®Google Scholar
• Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676-85
   PubMed Web of Science ®Google Scholar
• Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-27
   PubMed Web of Science ®Google Scholar
• Gianni L, Baselga J, Eiermann W, et al. European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF).J Clin Oncol (Meeting Abstracts) 2005;23(16S):513
   Google Scholar
• von MG, Kummel S, Vogel P, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100:552-62
   PubMedGoogle Scholar
• Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-32
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108-16
   PubMed Web of Science ®Google Scholar
• Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative ‘Arimidex‵ Compared to Tamoxifen (PROACT) trial. Cancer 2006;106:2095-103
   PubMed Web of Science ®Google Scholar
• Torrisi R, Dellapasqua S, Ghisini R, et al. Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. Breast 2008;17:654-60
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24:1940-9
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22
   PubMed Web of Science ®Google Scholar
• Ollivier L, Balu-Maestro C, Leclere J. Imaging in evaluation of response to neoadjuvant breast cancer treatment. Cancer Imaging 2005;5:27-31
   PubMedGoogle Scholar
• Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005;184:868-77
   PubMed Web of Science ®Google Scholar
• Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003;181:1275-82
   PubMed Web of Science ®Google Scholar
• Partridge SC, Gibbs JE, Lu Y, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 2005;184:1774-81
   PubMed Web of Science ®Google Scholar
• Moon HG, Han W, Lee JW, et al. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol 2009;20(4):636-41
   PubMed Web of Science ®Google Scholar
• Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 2008;112:17-26
   PubMed Web of Science ®Google Scholar
• Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008;14:6580-9
   PubMed Web of Science ®Google Scholar
• Chen JH, Feig BA, Hsiang DJ, et al. Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer. Ann Surg 2009;249:448-54
   PubMed Web of Science ®Google Scholar
• Bhattacharyya M, Ryan D, Carpenter R, et al. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2008;98:289-93
   PubMed Web of Science ®Google Scholar
• Buchholz TA, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol 2008;26:791-7
   PubMed Web of Science ®Google Scholar
• Ring AE, Smith IE, Ashley S, et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004;91:2012-7
   PubMed Web of Science ®Google Scholar
• Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9
   PubMed Web of Science ®Google Scholar
• Colleoni M, Bagnardi V, Rotmensz N, et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 2008 Oct 22. [Epub ahead of print]
   Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81
   PubMed Web of Science ®Google Scholar
• Peintinger F, Kuerer HM, Mcguire SE, et al. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg 2008;95:433-7
   PubMed Web of Science ®Google Scholar
• Peintinger F, Buzdar AU, Kuerer HM, et al. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 2008;19:2020-5
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005;23:41-8
   PubMed Web of Science ®Google Scholar
• Mieog JS, van der Hage JA, van de Vijver MJ, et al. Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression. Eur J Cancer 2006;42:1369-79
   PubMed Web of Science ®Google Scholar
• Faneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003;88:406-12
   PubMed Web of Science ®Google Scholar
• Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9
   PubMed Web of Science ®Google Scholar
• Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.Breast Cancer Res Treat 2009 Feb 13. [Epub ahead of print]
   Google Scholar
• Farmer P, Bonnefoi H, Anderle P, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009;15:68-74
   PubMed Web of Science ®Google Scholar
• Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93
   PubMed Web of Science ®Google Scholar
• Hannemann J, Oosterkamp HM, Bosch CA, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005;23:3331-42
   PubMed Web of Science ®Google Scholar
• Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 2008;19:496-500
   PubMed Web of Science ®Google Scholar
• Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008;14:7004-10
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102
   PubMedGoogle Scholar
• Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005;23:9304-11
   PubMed Web of Science ®Google Scholar
• Colleoni M, Bagnardi V, Rotmensz N, et al. A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer.Ann Oncol 2009 Feb 13. [Epub ahead of print]
   Google Scholar
• Jeruss JS, Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008;26:246-52
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hortobagyi GN. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer? J Natl Cancer Inst 2008;100:521-3
   PubMedGoogle Scholar
• Gonzalez-Angulo AM, Walters R, Broglio K, et al. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer 2008;8:516-21
   PubMed Web of Science ®Google Scholar
• Broadwater JR, Edwards MJ, Kuglen C, et al. Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity. Ann Surg 1991;213(2):126-9
   PubMed Web of Science ®Google Scholar
• Forouhi P, Dixon JM, Leonard RCF, et al. Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer. Br J Surg 1995;82(1):79-82
   PubMed Web of Science ®Google Scholar
• Pezner RD, Lorant JA, Terz J, et al. Wound-healing complications following biopsy of the irradiated breast. Arch Surg 1992;127(3):321-4
   PubMedGoogle Scholar
• Oh JL, Nguyen G, Whitman GJ, et al. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer 2007;110:2420-7
   PubMed Web of Science ®Google Scholar
• van Nes JG, Putter H, Julien JP, et al. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat 2009;115(1):101-13
   PubMed Web of Science ®Google Scholar
• Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 2004;22:2303-12
   PubMed Web of Science ®Google Scholar
• Huang EH, Strom EA, Perkins GH, et al. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys 2006;66:352-7
   PubMed Web of Science ®Google Scholar
• Bollet MA, Savignoni A, Pierga JY, et al. High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies. Br J Cancer 2008;98:734-41
   PubMed Web of Science ®Google Scholar
• Vo TN, Meric-Bernstam F, Yi M, et al. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 2006;192:552-5
   PubMed Web of Science ®Google Scholar
• Morrow M, Keeney K, Scholtens D, et al. Selecting patients for breast-conserving therapy: the importance of lobular histology. Cancer 2006;106:2563-8
   PubMed Web of Science ®Google Scholar
• Kuerer HM, Hunt KK. The rationale for integration of lymphatic mapping and sentinel node biopsy in the management of breast cancer patients receiving neoadjuvant chemotherapy. Semin Breast Dis 2002;5:80-7
   Google Scholar
• Xing Y, Foy M, Cox DD, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006;93:539-46
   PubMed Web of Science ®Google Scholar
• Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS + RT). Int J Radiat Oncol Biol Phys 2006;66:1320-7
   PubMed Web of Science ®Google Scholar
• Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-9
   PubMed Web of Science ®Google Scholar
• Frangioni JV. New technologies for human cancer imaging. J Clin Oncol 2008;26:4012-21
   PubMed Web of Science ®Google Scholar
• Kirsch DG, Dinulescu DM, Miller JB, et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 2007;13:992-7
   PubMed Web of Science ®Google Scholar
• Alencar H, Funovics MA, Figueiredo J, et al. Colonic adenocarcinomas: near-infrared microcatheter imaging of smart probes for early detection – study in mice. Radiology 2007;244:232-8
   PubMed Web of Science ®Google Scholar
• Weissleder R, Tung CH, Mahmood U, et al. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999;17:375-8
   PubMed Web of Science ®Google Scholar
• Sheth RA, Upadhyay R, Stangenberg L, et al. Improved detection of ovarian cancer metastases by intraoperative quantitative fluorescence protease imaging in a pre-clinical model. Gynecol Oncol 2009;112:616-22
   PubMed Web of Science ®Google Scholar
• Ishizawa T, Fukushima N, Shibahara J, et al. Real-time identification of liver cancers by using indocyanine green fluorescent imaging.Cancer 2009 Mar 26 [Epub ahead of print]
   PubMedGoogle Scholar
• Grimberg H, Levin G, Shirvan A, et al. Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis 2009;14:257-67
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Ito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8
   PubMed Web of Science ®Google Scholar
• Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007;26:1357-60
   PubMed Web of Science ®Google Scholar
• Phillips TM, Mcbride WH, Pajonk F. The response of CD24(-/low)/CD44 + breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-85
   PubMed Web of Science ®Google Scholar
• Jones RJ, Matsui WH, Smith BD. Cancer stem cells: are we missing the target? J Natl Cancer Inst 2004;96:583-5
   PubMed Web of Science ®Google Scholar
• Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-9
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005;23:2694-702
   PubMed Web of Science ®Google Scholar
• Newman EA, Sabel MS, Nees AV, et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol 2007;14(10):2946-52
   PubMed Web of Science ®Google Scholar
• Shen J, Gilcrease MZ, Babiera GV, et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 2007;109:1255-63
   PubMed Web of Science ®Google Scholar
• Gomez R, Zakhireh J, Moore D. Sentinel node biopsy performed in the neoadjuvant setting for breast cancer: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657). San Antonio Breast Cancer Symposium 2008;202
   Google Scholar
• Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009;27:726-32
   PubMed Web of Science ®Google Scholar
• Gimbergues P, Abrial C, Durando X, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol 2008;15:1316-21
   PubMed Web of Science ®Google Scholar